Errazquin R., Page A., Suñol A., Segrelles C., Carrasco E., Peral J., Garrido-Aranda A., Del Marro S., Ortiz J., Lorz C., Minguillon J., Surralles J., Belendez C., Alvarez M., Balmaña J., Bravo A., Ramirez A., Garcia-Escudero R.. Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia. ORAL ONCOLOGY. 2022; 134DOI:10.1016/j.oraloncology.2022.106184. PMID:36191479. IF:4.800(Q1/1D).

Sevilla, J, Navarro, S, Rio, P, Sanchez-Dominguez, R, Zubicaray, J, Galvez, E, Merino, E, Sebastian, E, Azqueta, C, Casado, JA, Segovia, JC, Alberquilla, O, Bogliolo, M, Roman-Rodriguez, FJ, Gimenez, Y, Larcher, L, Salgado, R, Pujol, RM, Hladun, R, Castillo, A, Soulier, J, Querol, S, Fernandez, J, Schwartz, J, de Andoin, NG, Lopez, R, Catala, A, Surralles, J, Diaz-de-Heredia, C, Bueren, JA. Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Molecular Therapy-Methods & Clinical Development. 2021; 22DOI:10.1016/j.omtm.2021.06.001. PMID:34485595. IF:5.849(Q2/4D).

Castells-Roca, L, Gutierrez-Enriquez, S, Bonache, S, Bogliolo, M, Carrasco, E, Aza-Carmona, M, Montalban, G, Munoz-Subirana, N, Pujol, R, Cruz, C, Llop-Guevara, A, Ramirez, MJ, Saura, C, Lasa, A, Serra, V, Diez, O, Balmana, J, Surralles, J. Clinical consequences of BRCA2 hypomorphism. npj Breast Cancer. 2021; 7(1)DOI:10.1038/s41523-021-00322-9. PMID:34504103. IF:7.519(Q1/3D).

Isla, D, de Castro, J, Garcia-Campelo, R, Majem, M, Vicente, D, Juan-Vidal, O. Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. Clinical & Translational Oncology. 2021; 23(7)DOI:10.1007/s12094-020-02518-0. PMID:33210237. IF:3.340(Q3/7D).

Garcia-Alfonso, P, Saiz-Rodriguez, M, Mondejar, R, Salazar, J, Paez, D, Borobia, AM, Safont, MJ, Garcia-Garcia, I, Colomer, R, Garcia-Gonzalez, X, Herrero, MJ, Lopez-Fernandez, LA, Abad-Santos, F. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical & Translational Oncology. 2022; 24(3)DOI:10.1007/s12094-021-02708-4. PMID:34773566. IF:3.400(Q3/6D).

Hentrich, MU, Bower, M, Daugaard, G, Dieing, A, Bickel, M, Berretta, M, Lesmeister, F, Jurinovic, V, Stoehr, A, Heinzelbecker, J, Krznaric, I, Dieckmann, KP, Necchi, A, Rey, PM, Rockstroh, JK, Brito, M, Pfister, D, Hoffmann, C. Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. CANCER. 2022; 128(2)DOI:10.1002/cncr.33928. PMID:34592009. IF:6.200(Q1/3D).

Blay, JY, Hindi, N, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Carvajal, B, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara, M, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, dei Tos, AP, Malagon, HRD, Donati, D, Dufresne, A, Eriksson, M, Farias-Loza, M, Fernandez, P, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gelderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, David, BBL, Lopez-Pousa, A, Lutter, G, Martinez-Said, H, Martinez-Tlahuel, J, Mello, CA, Perez, JMM, David, SM, Nascimento, AG, Ortiz-Cruz, EJ, Palmerini, E, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Salas, R, Santos, TTG, Scotlandi, K, Soule, T, Stacchiotti, S, Valverde, C, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. CANCER TREATMENT REVIEWS. 2022; 102DOI:10.1016/j.ctrv.2021.102312. PMID:34798363. IF:11.800(Q1/1D).

Provencio, M, Rodriguez-Abreu, D, Ortega, AL, Serrano, G, Aguado, C, Franco, F, Gutierrez, V, Vivanco, GL, Guirado, M, Benitez, G, Estival, A, Calvo, V, Jimenez, B, Arasanz, H, Coves, J, Majem, M, Massuti, B, Vazquez, S, Juan-Vidal, O, Collazo-Lorduy, A, Gozalvez, CL, Del Barco, E, Rosero, A, Bosch-Barrerra, J, Moreno, MA, Mielgo-Rubio, X, Villa, JC, Lopez-Martin, A, Cordoba, JF, Aparisi, FD, Zafra, M, Mosquera, J, Altozano, JP, Nadal, E, Catot, S, Balsalobre, J, De Portugal, T, Martin, P, De Juan, SC, Cobo, M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Translational Lung Cancer Research. 2022; 11(1)DOI:10.21037/tlcr-21-504. PMID:35242627. IF:4.000(Q2/4D).

Majem, M, Sullivan, I, Viteri, S, Lopez-Vivanco, G, Cobo, M, Sanchez, JM, Garcia-Gonzalez, J, Garde, J, Sampayo, M, Martrat, G, Malfettone, A, Karachaliou, N, Molina-Vila, MA, Rosell, R. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. EUROPEAN JOURNAL OF CANCER. 2021; 159DOI:10.1016/j.ejca.2021.09.039. PMID:34763195. IF:10.002(Q1/2D).

Cortellini, A, Ricciuti, B, Facchinetti, F, Alessi, JVM, Venkatraman, D, Dall'Olio, FG, Cravero, P, Vaz, VR, Ottaviani, D, Majem, M, Piedra, A, Sullivan, I, Lee, KA, Lamberti, G, Hussain, N, Clark, J, Bolina, A, Barba, A, Benitez, JC, Gorria, T, Mezquita, L, Hoton, D, Nana, FA, Besse, B, Awad, MM, Pinato, DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. ANNALS OF ONCOLOGY. 2021; 32(11)DOI:10.1016/j.annonc.2021.08.1744. PMID:34400292. IF:51.769(Q1/1D).

Rofes, P, Gonzalez, S, Navarro, M, Moreno-Cabrera, JM, Solanes, A, Darder, E, Carrasco, E, Iglesias, S, Salinas, M, Gomez, C, Velasco, A, Tuset, N, Varela, M, Llort, G, Cajal, TRY, Grau, E, Duenas, N, Merlano, ND, Matias-Guiu, X, Rivera, B, Balmana, J, Pineda, M, Brunet, J, Capella, G, del Valle, J, Lazaro, C. Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer-Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. JOURNAL OF MOLECULAR DIAGNOSTICS. 2021; 23(11)DOI:10.1016/j.jmoldx.2021.07.024. PMID:34454113. IF:5.341(Q1/3D).

Gronchi, A, Miah, AB, DeiTos, AP, Abecassis, N, Bajpai, J, Bauer, S, Biagini, R, Bielack, S, Blay, JY, Bolle, S, Bonvalot, S, Boukovinas, I, Bovee, JVMG, Boye, K, Brennan, B, Brodowicz, T, Buonadonna, A, DeAlava, E, Del Muro, XG, Dufresne, A, Eriksson, M, Fagioli, F, Fedenko, A, Ferraresi, V, Ferrari, A, Frezza, AM, Gasperoni, S, Gelderblom, H, Gouin, F, Grignani, G, Haas, R, Hassan, AB, Hecker-Nolting, S, Hindi, N, Hohenberger, P, Joensuu, H, Jones, RL, Jungels, C, Jutte, P, Kager, L, Kasper, B, Kawai, A, Kopeckova, K, Krakorova, DA, Le Cesne, A, LeGrange, F, Legius, E, Leithner, A, Lopez-Pousa, A, Martin-Broto, J, Merimsky, O, Messiou, C, Mir, O, Montemurro, M, Morland, B, Morosi, C, Palmerini, E, Pantaleo, MA, Piana, R, Piperno-Neumann, S, Reichardt, P, Rutkowski, P, Safwat, AA, Sangalli, C, Sbaraglia, M, Scheipl, S, Schoffski, P, Sleijfer, S, Strauss, D, Strauss, S, SundbyHall, K, Trama, A, Unk, M, VandeSande, MAJ, VanderGraaf, WTA, van Houdt, WJ, Frebourg, T, Casali, PG, Stacchiotti, S, ESMO Guidelines Comm, EURACAN, GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY. 2021; 32(11)DOI:10.1016/j.annonc.2021.07.006. PMID:34303806. IF:51.769(Q1/1D).

Dabush, DR, Shepshelovich, D, Shochat, T, Tibau, A, Amir, E, Goldvaser, H. The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. CANCER TREATMENT REVIEWS. 2021; 100DOI:10.1016/j.ctrv.2021.102293. PMID:34543860. IF:13.608(Q1/1D).

Casarrubios, M, Cruz-Bermudez, A, Nadal, E, Insa, A, Campelo, MDG, Lazaro, M, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, de Castro-Carpeno, J, Cobo, M, Lopez-Vivanco, G, Del Barco, E, Caro, RB, Vinolas, N, Aranda, IB, Viteri, S, Massuti, B, Barquin, M, Laza-Briviesca, R, Sierra-Rodero, B, Parra, ER, Sanchez-Espiridion, B, Rocha, P, Kadara, H, Wistuba, II, Romero, A, Calvo, V, Provencio, M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. CLINICAL CANCER RESEARCH. 2021; 27(21)DOI:10.1158/1078-0432.CCR-21-1200. PMID:34376534. IF:13.801(Q1/1D).

Wu, YL, Tsuboi, M, John, T, Grohe, C, Majem, M, Goldman, JW, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Hodge, R, Atasoy, A, Rukazenkov, Y, Herbst, RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology. 2021; 17(35)DOI:10.2217/fon-2021-0752. PMID:34723634. IF:3.674(Q3/7D).

Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, McHugh, J, Jones, AB, Karlsson, Q, Merson, S, Ong, KR, Hoffman, J, Huber, C, Maehle, L, Grindedal, EM, Stormorken, A, Evans, DG, Rothwell, J, Lalloo, F, Brady, AF, Bartlett, M, Snape, K, Hanson, H, James, P, McKinley, J, Mascarenhas, L, Syngal, S, Ukaegbu, C, Side, L, Thomas, T, Barwell, J, Teixeira, MR, Izatt, L, Suri, M, Macrae, FA, Poplawski, N, Chen-Shtoyerman, R, Ahmed, M, Musgrave, H, Nicolai, N, Greenhalgh, L, Brewer, C, Pachter, N, Spigelman, AD, Azzabi, A, Helfand, BT, Halliday, D, Buys, S, Cajal, TRY, Donaldson, A, Cooney, KA, Harris, M, McGrath, J, Davidson, R, Taylor, A, Cooke, P, Myhill, K, Hogben, M, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Dias, A, Dudderidge, T, Eccles, DM, Green, K, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lilja, H, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, AV, Moynihan, C, Raghallaigh, HN, Rennert, G, Collier, R, Offman, J, Kote-Jarai, Z, Eeles, RA. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. LANCET ONCOLOGY. 2021; 22(11)DOI:10.1016/S1470-2045(21)00522-2. PMID:34678156. IF:54.433(Q1/1D).

Riera, P, Paez, D. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. Expert Opinion on Drug Metabolism & Toxicology. 2021; 17(10)DOI:10.1080/17425255.2021.1974397. PMID:34486919. IF:4.936(Q1/3D).

Herbst, RS, Garon, EB, Kim, DW, Cho, BC, Gervais, R, Perez-Gracia, JL, Han, JY, Majem, M, Forster, MD, Monnet, I, Novello, S, Gubens, MA, Boyer, M, Su, WC, Samkari, A, Jensen, EH, Kobie, J, Piperdi, B, Baas, P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. Research in Social & Administrative Pharmacy. 2021; 16(10)DOI:10.1016/j.jtho.2021.05.001. PMID:34048946. IF:3.348(Q2/5D).

Ribelles, N, Alvarez-Lopez, I, Arcusa, A, Chacon, JI, de la Haba, J, Garcia-Corbacho, J, Garcia-Mata, J, Jara, C, Jerez, JM, Lazaro-Quintela, M, Leon-Mateos, L, Ramirez-Merino, N, Tibau, A, Garcia-Palomo, A. Electronic health records and patient registries in medical oncology departments in Spain. Clinical & Translational Oncology. 2021; 23(10)DOI:10.1007/s12094-021-02614-9. PMID:33864619. IF:3.340(Q3/7D).

Riudavets, M, Sullivan, I, Abdayem, P, Planchard, D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021; 6(5)DOI:10.1016/j.esmoop.2021.100260. PMID:34479034. IF:6.883(Q1/3D).

Blackhall, F, Jao, K, Greillier, L, Cho, BC, Penkov, K, Reguart, N, Majem, M, Nackaerts, K, Syrigos, K, Hansen, K, Schuette, W, Cetnar, J, Cappuzzo, F, Okamoto, I, Erman, M, Langer, SW, Kato, T, Groen, H, Sun, ZW, Luo, Y, Tanwani, P, Caffrey, L, Komarnitsky, P, Reinmuth, N. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology. 2021; 16(9)DOI:10.1016/j.jtho.2021.02.009. PMID:33607312. IF:20.121(Q1/1D).

Garrido, P, Paz-Ares, L, Majem, M, Moran, T, Trigo, JM, Bosch-Barrera, J, Garcia-Campelo, R, Gonzalez-Larriba, JL, Sanchez-Torres, JM, Isla, D, Vinolas, N, Camps, C, Insa, A, Juan, O, Massuti, B, Paredes, A, Artal, A, Lopez-Brea, M, Palacios, J, Felip, E. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 2021; 10(17)DOI:10.1002/cam4.4135. PMID:34296539. IF:4.711(Q2/5D).

Vokinger, KN, Hwang, TJ, Daniore, P, Lee, CC, Tibau, A, Grischott, T, Rosemann, TJ, Kesselheim, AS. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncology. 2021; 7(9)DOI:10.1001/jamaoncol.2021.2026. PMID:34196656. IF:33.012(Q1/1D).

Moreno, V, Greil, R, Yachnin, J, Majem, M, Wermke, M, Arkenau, HT, Basque, JR, Nidamarthy, PK, Kapoor, S, Cui, XM, Giovannini, M. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. CLINICAL THERAPEUTICS. 2021; 43(6)DOI:10.1016/j.clinthera.2021.04.006. PMID:34053700. IF:3.637(Q2/5D).

Jimenez-Labaig, P, Pacheco-Barcia, V, Cebria, A, Galvez, F, Obispo, B, Paez, D, Quilez, A, Quintanar, T, Ramchandani, A, Remon, J, Rogado, J, Sanchez, DA, Sanchez-Canovas, M, Sanz-Garcia, E, Sesma, A, Tarazona, N, Cotes, A, Gonzalez, E, Bosch-Barrera, J, Fernandez, A, Felip, E, Vera, R, Rodriguez-Lescure, A, Elez, E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021; 6(4)DOI:10.1016/j.esmoop.2021.100215. PMID:34325108. IF:6.883(Q1/3D).

Wilson, BE, Desnoyers, A, Nadler, MB, Tibau, A, Amir, E. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. Cancer Medicine. 2021; 10(16)DOI:10.1002/cam4.4029. PMID:34323019. IF:4.711(Q2/5D).

Gil-Gil, MJ, Bellet, M, Bergamino, M, Morales, S, Barnadas, A, Manso, L, Saura, C, Fernandez-Ortega, A, Garcia-Martinez, E, Martinez-Janez, N, Mele, M, Villagrasa, P, Celiz, P, Martin, XP, Ciruelos, E, Pernas, S. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Frontiers in Oncology. 2021; 11DOI:10.3389/fonc.2021.645026. PMID:34307126. IF:5.738(Q2/4D).

Provencio, M, Gallego, JMM, Calles, A, Antonanzas, M, Pangua, C, Rubio, XM, Nadal, E, Castro, RL, Lopez-Martin, A, Del Barco, E, Domine, M, Franco, F, Diz, P, Sandoval, C, Girona, ES, Sullivan, I, Sala, MA, Ledo, GG, Cucurull, M, Mosquera, J, Martinez, M, Chara, LE, Arriola, E, Herrera, BE, Jarabo, JR, Alvarez, RA, Baena, J, Cao, MG. Lung cancer patients with COVID-19 in Spain: GRAVID study. LUNG CANCER. 2021; 157DOI:10.1016/j.lungcan.2021.05.014. PMID:34016490. IF:6.081(Q1/3D).

Mezquita, L, Preeshagul, I, Auclin, E, Saravia, D, Hendriks, L, Rizvi, H, Park, W, Nadal, E, Martin-Romano, P, Ruffinelli, JC, Ponce, S, Audigier-Valette, C, Carnio, S, Blanc-Durand, F, Bironzo, P, Tabbo, F, Reale, ML, Novello, S, Hellmann, MD, Sawan, P, Girshman, J, Plodkowski, AJ, Zalcman, G, Majem, M, Charrier, M, Naigeon, M, Rossoni, C, Mariniello, A, Paz-Ares, L, Dingemans, AM, Planchard, D, Cozic, N, Cassard, L, Lopes, G, Chaput, N, Arbour, K, Besse, B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. EUROPEAN JOURNAL OF CANCER. 2021; 151DOI:10.1016/j.ejca.2021.03.011. PMID:34022698. IF:10.002(Q1/2D).

Alvarez-Mancenido, F, Jimenez-Fonseca, P, Carmona-Bayonas, A, Arrazubi, V, Hernandez, R, Cano, JM, Custodio, A, Pijaume, CP, Aguado, G, Lago, NM, Canovas, MS, Lavin, DC, Visa, L, Martinez-Torron, A, Arias-Martinez, A, Lopez, F, Limon, ML, Tocino, RV, Montes, AF, Alsina, M, Pimentel, P, Reguera, P, Carnicero, AM, Ramchandani, A, Granja, M, Azkarate, A, Richard, MM, Serra, O, Perez, CH, Hurtado, A, Gil-Negrete, A, Sauri, T, del Burgo, PM, Gallego, J. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer. 2021; 24(4)DOI:10.1007/s10120-021-01169-6. PMID:33651195. IF:7.701(Q1/2D).

Laza-Briviesca, R, Cruz-Bermudez, A, Nadal, E, Insa, A, Garcia-Campelo, MD, Huidobro, G, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, Carpeno, JD, Cobo, M, Vivanco, GL, Del Barco, E, Caro, RB, Vinolas, N, Aranda, IB, Viteri, S, Massuti, B, Casarrubios, M, Sierra-Rodero, B, Tarin, C, Garcia-Grande, A, Haymaker, C, Wistuba, II, Romero, A, Franco, F, Provencio, M. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine. 2021; 11(7)DOI:10.1002/ctm2.491. PMID:34323406. IF:8.554(Q1/2D).

Atenza, CZ, Anguera, G, Melia, MR, De Lamo, LA, Sullivan, I, Joaquin, AB, Lopez, JS, Ortiz, MA, Mulet, M, Vidal, S, Majem, M. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2022; 71(8)DOI:10.1007/s00262-021-03107-y. PMID:34984538. IF:5.800(Q1/3D).

Arriola, E, Gonzalez-Cao, M, Domine, M, De Castro, J, Cobo, M, Bernabe, R, Navarro, A, Sullivan, I, Trigo, JM, Mosquera, J, Crama, L, Isla, D. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncology And Therapy. 2022; 10(1)DOI:10.1007/s40487-021-00182-0. PMID:35032007. IF:(Q/D).

Remon, J, Bernabe, R, Diz, P, Felip, E, Gonzalez-Larriba, JL, Lazaro, M, Mielgo-Rubio, X, Sanchez, A, Sullivan, I, Massutti, B. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02788-w. PMID:35122634. IF:3.400(Q3/6D).

Capdevila, J, Gomez, MA, Guillot, M, Paez, D, Pericay, C, Safont, MJ, Tarazona, N, Vera, R, Vidal, J, Sastre, J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02816-9. PMID:35303269. IF:3.400(Q3/6D).

Palassini, E, Mir, O, Grignani, G, Vincenzi, B, Gelderblom, H, Sebio, A, Valverde, C, Baldi, GG, Brunello, A, Cardellino, GG, Marrari, A, Badalamenti, G, Martin-Broto, J, Ferraresi, V, Libertini, M, Turano, S, Gataa, I, Collini, P, Dei Tos, AP, Gennaro, M, Bini, F, Provenzano, S, Lo Vullo, S, Mariani, L, Le Cesne, A, Casali, PG. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. BREAST CANCER RESEARCH AND TREATMENT. 2022; 192(3)DOI:10.1007/s10549-022-06524-4. PMID:35150367. IF:3.800(Q2/5D).

Eggermont, AMM, Ascierto, PA, Khushalani, NI, Schadendorf, D, Boland, G, Weber, J, Lewis, KD, Johnson, D, Rivalland, G, Khattak, A, Majem, M, Gogas, H, Long, GV, Currie, SL, Chien, D, Tagliaferri, MA, Carlino, MS, Diab, A. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology. 2022; 18(8)DOI:10.2217/fon-2021-1286. PMID:35073733. IF:3.300(Q3/6D).

Sanchez, A, Roos, VH, Navarro, M, Pineda, M, Caballol, B, Moreno, L, Carballal, S, Rodriguez-Alonso, L, Cajal, TRY, Llort, G, Pinol, V, Lopez-Fernandez, A, Salces, I, Pico, MD, Rivas, L, Bujanda, L, Garzon, M, Pizarro, A, de Castro, EM, Lopez-Arias, MJ, Poves, C, Garau, C, Rodriguez-Alcalde, D, Herraiz, M, Alvarez-Urrutia, C, Dacal, A, Carrillo-Palau, M, Cid, L, Ponce, M, Barreiro-Alonso, E, Saperas, E, Aguirre, E, Romero, C, Bastiaansen, B, Gonzalez-Acosta, M, Morales-Romero, B, Ocana, T, Rivero-Sanchez, L, Jung, G, Bessa, X, Cubiella, J, Jover, R, Rodriguez-Moranta, F, Balmana, J, Brunet, J, Castells, A, Dekker, E, Capella, G, Serra-Burriel, M, Moreira, L, Pellise, M, Balaguer, F. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology. 2022; 20(3)DOI:10.1016/j.cgh.2020.11.002. PMID:33157315. IF:12.600(Q1/1D).

Wu, YL, John, T, Grohe, C, Majem, M, Goldman, JW, Kim, SW, Kato, T, Laktionov, K, Vu, HV, Wang, ZJ, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Atasoy, A, Herbst, RS, Tsuboi, M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 2022; 17(3)DOI:10.1016/j.jtho.2021.10.014. PMID:34740861. IF:20.400(Q1/1D).

Sooy, RA, Han, JY, Dafni, U, Cho, BC, Yeo, CM, Nadal, E, Carcereny, E, de Castro, J, Sala, MA, Bernabee, R, Coate, L, Pulla, MP, Campelo, RG, Cuffe, S, Hashemi, SMS, Fruh, M, Massuti, B, Garcia-Sanchez, J, Domine, M, Majem, M, Sanchez-Torres, JM, Britschgi, C, Pless, M, Dimopoulou, G, Roschitzki-Voser, H, Ruepp, B, Rosell, R, Stahel, RA, Peters, S. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. ANNALS OF ONCOLOGY. 2022; 33(2)DOI:10.1016/j.annonc.2021.11.010. PMID:34839016. IF:50.500(Q1/1D).